IL263653A - History of azabenzimidazole as PI3K inhibitors in the cell - Google Patents
History of azabenzimidazole as PI3K inhibitors in the cellInfo
- Publication number
- IL263653A IL263653A IL263653A IL26365318A IL263653A IL 263653 A IL263653 A IL 263653A IL 263653 A IL263653 A IL 263653A IL 26365318 A IL26365318 A IL 26365318A IL 263653 A IL263653 A IL 263653A
- Authority
- IL
- Israel
- Prior art keywords
- beta inhibitors
- pi3k beta
- azabenzimidazole derivatives
- azabenzimidazole
- derivatives
- Prior art date
Links
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical class C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16174712 | 2016-06-16 | ||
| PCT/EP2017/064672 WO2017216293A1 (en) | 2016-06-16 | 2017-06-15 | Azabenzimidazole derivatives as pi3k beta inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL263653A true IL263653A (en) | 2019-01-31 |
Family
ID=56132833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL263653A IL263653A (en) | 2016-06-16 | 2018-12-11 | History of azabenzimidazole as PI3K inhibitors in the cell |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190263804A1 (enExample) |
| EP (1) | EP3472147B1 (enExample) |
| JP (1) | JP7158286B2 (enExample) |
| KR (1) | KR102472198B1 (enExample) |
| CN (1) | CN109311843B (enExample) |
| AU (1) | AU2017286380B2 (enExample) |
| BR (1) | BR112018076169A2 (enExample) |
| EA (1) | EA037871B1 (enExample) |
| ES (1) | ES2818620T3 (enExample) |
| IL (1) | IL263653A (enExample) |
| MX (1) | MX375484B (enExample) |
| WO (1) | WO2017216293A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019197468A1 (en) | 2018-04-12 | 2019-10-17 | Bayer Aktiengesellschaft | N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| JP7349450B2 (ja) | 2018-04-25 | 2023-09-22 | バイエル・アクチエンゲゼルシヤフト | 殺有害生物剤としての新規ヘテロアリール－トリアゾール化合物及びヘテロアリール－テトラゾール化合物 |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| JP7691973B2 (ja) | 2019-07-23 | 2025-06-12 | バイエル・アクチエンゲゼルシヤフト | 殺有害生物剤としての新規なヘテロアリール－トリアゾール化合物 |
| CN110551101B (zh) * | 2019-08-28 | 2020-11-24 | 沈阳药科大学 | 1、6-二取代-苯并五元杂环类衍生物及其用途 |
| CN117567338A (zh) | 2019-10-09 | 2024-02-20 | 拜耳公司 | 作为农药的新的杂芳基三唑化合物 |
| WO2021154662A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| KR20220132594A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| CN115210235A (zh) | 2020-01-27 | 2022-10-18 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| CN115279765B (zh) | 2020-01-27 | 2024-11-12 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| JP2023512206A (ja) | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| JP7712941B2 (ja) | 2020-01-27 | 2025-07-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| JP7684316B2 (ja) | 2020-01-27 | 2025-05-27 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| US20230127326A1 (en) | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| CN115151547A (zh) | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| US20250382289A1 (en) * | 2022-02-18 | 2025-12-18 | Xizang Haisco Pharmaceutical Co., Ltd. | Pyrazolopyridine derivative and application thereof in medicine |
| WO2024222880A1 (zh) * | 2023-04-27 | 2024-10-31 | 西藏海思科制药有限公司 | 一种吡啶并吡唑衍生物的药物组合物及其在医药上的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5177074A (en) * | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| US20090170848A1 (en) | 2006-03-02 | 2009-07-02 | Smithkline Beecham Corporation | Thiazolones for use as pi3 kinase inhibitors |
| EP2046333A4 (en) | 2006-07-24 | 2010-09-15 | Glaxosmithkline Llc | THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE |
| JP2010535804A (ja) | 2007-08-09 | 2010-11-25 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体 |
| ES2406129T3 (es) * | 2007-10-05 | 2013-06-05 | Verastem, Inc. | Derivados de purina sustituidos con pirimidina |
| BRPI0906473A8 (pt) | 2008-01-04 | 2016-02-10 | Intellikine Inc | Certas entidades químicas, composições e métodos |
| UA111579C2 (uk) | 2009-08-17 | 2016-05-25 | Інтеллікіне Ллк | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ |
| US8569296B2 (en) | 2009-09-29 | 2013-10-29 | Xcovery Holding Company, Llc | PI3K (delta) selective inhibitors |
| UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| KR101594002B1 (ko) | 2010-10-06 | 2016-02-15 | 글락소스미스클라인 엘엘씨 | Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체 |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| WO2013028263A1 (en) | 2011-08-24 | 2013-02-28 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as pi3 kinase inhibitors |
| US8906910B2 (en) | 2011-12-20 | 2014-12-09 | Glaxosmithkline Llc | Imidazopyridine derivatives as PI3 kinase |
| US8778937B2 (en) | 2011-12-20 | 2014-07-15 | Glaxosmithkline Llc | Benzimidazole boronic acid derivatives as PI3 kinase inhibitors |
-
2017
- 2017-06-15 EA EA201892734A patent/EA037871B1/ru not_active IP Right Cessation
- 2017-06-15 BR BR112018076169-9A patent/BR112018076169A2/pt not_active Application Discontinuation
- 2017-06-15 MX MX2018015709A patent/MX375484B/es active IP Right Grant
- 2017-06-15 EP EP17729500.3A patent/EP3472147B1/en active Active
- 2017-06-15 AU AU2017286380A patent/AU2017286380B2/en not_active Ceased
- 2017-06-15 US US16/310,413 patent/US20190263804A1/en not_active Abandoned
- 2017-06-15 WO PCT/EP2017/064672 patent/WO2017216293A1/en not_active Ceased
- 2017-06-15 KR KR1020187037717A patent/KR102472198B1/ko active Active
- 2017-06-15 ES ES17729500T patent/ES2818620T3/es active Active
- 2017-06-15 CN CN201780037153.5A patent/CN109311843B/zh active Active
- 2017-06-15 JP JP2018565868A patent/JP7158286B2/ja active Active
-
2018
- 2018-12-11 IL IL263653A patent/IL263653A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017286380A1 (en) | 2018-12-06 |
| BR112018076169A2 (pt) | 2019-03-26 |
| AU2017286380B2 (en) | 2021-02-04 |
| MX2018015709A (es) | 2019-03-21 |
| EP3472147B1 (en) | 2020-06-17 |
| EP3472147A1 (en) | 2019-04-24 |
| JP7158286B2 (ja) | 2022-10-21 |
| CN109311843A (zh) | 2019-02-05 |
| MX375484B (es) | 2025-03-06 |
| KR102472198B1 (ko) | 2022-11-28 |
| KR20190016976A (ko) | 2019-02-19 |
| CN109311843B (zh) | 2021-10-08 |
| CA3025746A1 (en) | 2017-12-21 |
| WO2017216293A1 (en) | 2017-12-21 |
| US20190263804A1 (en) | 2019-08-29 |
| JP2019518059A (ja) | 2019-06-27 |
| ES2818620T3 (es) | 2021-04-13 |
| EA201892734A1 (ru) | 2019-05-31 |
| EA037871B1 (ru) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254318B (en) | History of benzaimidazoles as bromodomain inhibitors | |
| PL3218378T3 (pl) | Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych | |
| IL246140B (en) | History of bicyclic heterocyclics as bromodomain repressors | |
| SG11201509220XA (en) | Benzimidazole derivatives as bromodomain inhibitors | |
| AP2015008783A0 (en) | 6-(5-hydroxy-1h-pyrazol-1-yl) nicotinamida derivatives and their use as phd inhibitors | |
| ZA201608637B (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
| IL244609B (en) | History of 4-azaindole | |
| SG11201605810WA (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| AP2016009661A0 (en) | Quinolizinone derivatives as pi3k inhibitors | |
| IL258438B (en) | 2-Aminoquinoline derivatives as p70s6 kinase inhibitors | |
| ZA201705530B (en) | 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors | |
| IL252866B (en) | History of imidazopyridazine as pi3k beta inhibitors | |
| SG10201404643XA (en) | Nitrogen Containing Heterocyclic PI3K δ Inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |